A detailed history of Plato Investment Management LTD transactions in Exact Sciences Corp stock. As of the latest transaction made, Plato Investment Management LTD holds 7,856 shares of EXAS stock, worth $451,562. This represents 0.04% of its overall portfolio holdings.

Number of Shares
7,856
Previous 8,118 3.23%
Holding current value
$451,562
Previous $343 Million 55.87%
% of portfolio
0.04%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$42.43 - $70.83 $11,116 - $18,557
-262 Reduced 3.23%
7,856 $535 Million
Q2 2024

Aug 08, 2024

SELL
$41.33 - $74.26 $149,986 - $269,489
-3,629 Reduced 30.89%
8,118 $343 Million
Q1 2024

May 14, 2024

BUY
$56.27 - $73.77 $641,646 - $841,199
11,403 Added 3314.83%
11,747 $1.24 Billion
Q4 2023

Feb 12, 2024

BUY
$59.06 - $75.72 $20,316 - $26,047
344 New
344 $25.4 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Plato Investment Management LTD Portfolio

Follow Plato Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Plato Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Plato Investment Management LTD with notifications on news.